PHVS - Pharvaris BV - Stock Price & Dividends

Pharvaris BV, a cutting-edge biopharmaceutical company, is dedicated to developing and commercializing innovative therapies for rare diseases, aiming to improve the lives of patients worldwide.

The company's pipeline is focused on addressing hereditary angioedema (HAE), a debilitating genetic disorder characterized by recurring episodes of swelling. Pharvaris is developing a range of novel treatments, including PHA121, a small molecule bradykinin B2-receptor antagonist designed to tackle the root cause of HAE.

In addition, Pharvaris is advancing two other promising candidates: PHVS416, an on-demand, rapid exposure soft capsule for acute HAE attacks, currently in Phase 2 clinical trials; and PHVS719, a prophylactic extended-release tablet for HAE patients, currently in Phase 1 clinical trials. These innovative treatments have the potential to revolutionize the management of HAE, providing patients with more effective and convenient options.

With operations in the Netherlands, Switzerland, and the United States, Pharvaris is well-positioned to leverage its global expertise and resources to drive innovation and access to rare disease treatments. Founded in 2015, the company is headquartered in Leiden, the Netherlands, and is committed to making a meaningful impact in the lives of patients and their families.

For more information, please visit Pharvaris' website at https://pharvaris.com.